Patents Assigned to NORTHEAST OHIO MEDICAL UNIVERSITY
-
Patent number: 11938106Abstract: A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described.Type: GrantFiled: April 18, 2022Date of Patent: March 26, 2024Assignee: NORTHEAST OHIO MEDICAL UNIVERSITYInventor: Alexander V. Galazyuk
-
Publication number: 20240082357Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.Type: ApplicationFiled: November 22, 2023Publication date: March 14, 2024Applicants: SUMMA HEALTH, NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Marc S. PENN, Maritza MAYORGA, Matthew KIEDROWSKI
-
Patent number: 11911384Abstract: A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator.Type: GrantFiled: May 9, 2022Date of Patent: February 27, 2024Assignee: NORTHEAST OHIO MEDICAL UNIVERSITYInventors: William M. Chilian, Vahagn Ohanyan, Liya Yin
-
Patent number: 11554158Abstract: A method for treating a skin wound of a subject is described. The method includes contacting the skin wound with a therapeutically effective amount of a wound healing composition comprising glycoprotein nonmelanoma clone B (GPNMB) protein, an active peptide fragment thereof, a GPNMB analog, a GPNMB potentiating agent, or a combination thereof.Type: GrantFiled: April 13, 2017Date of Patent: January 17, 2023Assignees: NORTHEAST OHIO MEDICAL UNIVERSITY, KENT STATE UNIVERSITYInventors: Min-Ho Kim, Fayez Safadi, Bing Yu
-
Publication number: 20220233653Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.Type: ApplicationFiled: February 8, 2022Publication date: July 28, 2022Applicants: SUMMA HEALTH, NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Marc S. PENN, Matthew Kiedrowski, Maritza Mayorga
-
Patent number: 11324748Abstract: A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator.Type: GrantFiled: April 23, 2018Date of Patent: May 10, 2022Assignee: NORTHEAST OHIO MEDICAL UNIVERSITYInventors: William M. Chilian, Vahagn Ohanyan, Liya Yin
-
Patent number: 11304917Abstract: A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described.Type: GrantFiled: February 19, 2016Date of Patent: April 19, 2022Assignee: NORTHEAST OHIO MEDICAL UNIVERSITYInventor: Alexander V. Galazyuk
-
Patent number: 11273208Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.Type: GrantFiled: May 31, 2017Date of Patent: March 15, 2022Assignees: Summa Health, Northeast Ohio Medical UniversityInventors: Marc S. Penn, Matthew Kiedrowski, Maritza Mayorga
-
Patent number: 11058707Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.Type: GrantFiled: November 2, 2018Date of Patent: July 13, 2021Assignee: Northeast Ohio Medical UniversityInventor: Charles K. Thodeti
-
Patent number: 11028140Abstract: A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition.Type: GrantFiled: September 22, 2015Date of Patent: June 8, 2021Assignee: Northeast Ohio Medical UniversityInventor: Fayez Safadi
-
Publication number: 20210113662Abstract: Provided herein are methods to promote tissue healing, to treat tissue injury or to treat a condition related to tissue injury comprising administering to a subject in need thereof an effective amount of one or both of: a CAMKK1 polypeptide or an equivalent thereof; or an SDF-1 polypeptide or an equivalent thereof, in the presence of CXCR4 polypeptide expression, wherein the effective amount is an amount that induces exosome production, secretion and/or function in the subject. Recombinant stem cells are also provided that overexpress one or both of a CAMKK1 protein or polypeptide and/or an SDF-1 protein or polypeptides. The stem cells and products produced from them are useful to treat ischemic or inflammatory conditions as well as to promote tissue healing.Type: ApplicationFiled: April 17, 2019Publication date: April 22, 2021Applicants: SUMMA HEALTH, NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Marc S. PENN, Maritza MAYORGA, Matthew KIEDROWSKI
-
Publication number: 20200000837Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.Type: ApplicationFiled: November 2, 2018Publication date: January 2, 2020Applicant: Northeast Ohio Medical UniversityInventor: Charles K. Thodeti
-
Publication number: 20190201489Abstract: In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of a zinc-finger CCHC domain-containing protein 6 (ZCCHC6) inhibitor. Methods can include administering a therapeutically effective amount of the ZCCHC6 inhibitor to the subject.Type: ApplicationFiled: June 28, 2017Publication date: July 4, 2019Applicant: NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Fayez SAFADI, Tariq HAQQI
-
Publication number: 20190134154Abstract: A method for treating a skin wound of a subject is described. The method includes contacting the skin wound with a therapeutically effective amount of a wound healing composition comprising glycoprotein nonmelanoma clone B (GPNMB) protein, an active peptide fragment thereof, a GPNMB analog, a GPNMB potentiating agent, or a combination thereof.Type: ApplicationFiled: April 13, 2017Publication date: May 9, 2019Applicant: Northeast Ohio Medical UniversityInventors: Min-Ho KIM, Fayez SAFADI, Bing YU
-
Publication number: 20170340712Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.Type: ApplicationFiled: May 31, 2017Publication date: November 30, 2017Applicants: SUMMA HEALTH, NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Marc S. PENN, Matthew KIEDROWSKI, Maritza MAYORGA
-
Publication number: 20140357711Abstract: Methods for synthesizing amooranin (25-hydroxy-3-oxoolean-12-en-28-oic acid (AMR) and/or amooranin analogs, including amooranin methyl ester (AMR-Me), by using oleanolic acid in an oxidation process, and therapeutic uses thereof are described.Type: ApplicationFiled: December 21, 2012Publication date: December 4, 2014Applicants: ENZYME BIO SYSTEMS, NORTHEAST OHIO MEDICAL UNIVERSITYInventors: Anupam Bishayee, Ashot Martirosian, Anushavan Yeranosyan
-
Publication number: 20130150432Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.Type: ApplicationFiled: June 22, 2011Publication date: June 13, 2013Applicants: NORTHEAST OHIO MEDICAL UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Charles K Thodeti, Donald E. Ingber